Cyrill A Rentsch
Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer.
Vlajnic T, Muller D, Ruiz C, Schönegg R, Seifert H, Thalmann G, Zellweger T, Le Magnen C, Rentsch C, Bubendorf L. Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer. Cancer Rep (Hoboken) 2023:e1953.
26.12.2023Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer.
26.12.2023Cancer Rep (Hoboken) 2023:e1953
Vlajnic Tatjana, Muller David C, Ruiz Christian, Schönegg René, Seifert Hans-Helge, Thalmann George N, Zellweger Tobias, Le Magnen Clémentine, Rentsch Cyrill A, Bubendorf Lukas
Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.
Neubauer M, Nicolas G, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, Forrer F, Rentsch C, Stenner-Liewen F, Templeton A, Schäfer N, Wild D, Chirindel A, all investigators on behalf of the SSNM Therapy Working Group. Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging 2023
01.12.2023Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.
01.12.2023Eur J Nucl Med Mol Imaging 2023
Neubauer Moritz C, Nicolas Guillaume, Bauman Andreas, Fani Melpomeni, Nitzsche Egbert U, Afshar-Oromieh Ali, Forrer Flavio, Rentsch Cyrill A, Stenner-Liewen Frank, Templeton Arnoud J, Schäfer Niklaus G, Wild Damian, Chirindel Alin, all investigators on behalf of the SSNM Therapy Working Group
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch C, Roth B, Bosshard P, Püschel H, Boll D, Hefermehl L, Roghmann F, Gierth M, Ribi K, Schäfer S, Wicki A, Bubendorf L, Torpai R, Thalmann G, Lucca I, Kwiatkowski M, Wirth G, Strebel R, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Hayoz S. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. Eur Urol Oncol 2022; 5:195-202.
07.01.2022A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
07.01.2022Eur Urol Oncol 2022; 5:195-202
Rentsch Cyrill A, Roth Beat, Bosshard Piet, Püschel Heike, Boll Daniel T, Hefermehl Lukas, Roghmann Florian, Gierth Michael, Ribi Karin, Schäfer Simon, Wicki Andreas, Bubendorf Lukas, Torpai Raimund, Thalmann George N, Lucca Ilaria, Kwiatkowski Maciej, Wirth Grégory J, Strebel Räto T, Engeler Daniel, Pedrazzini Augusto, Hüttenbrink Clemens, Schultze-Seemann Wolfgang, Hayoz Stefanie
[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]
Omlin A, Zwahlen D, Wyler S, Wild D, Templeton A, Stenner F, Schmid H, Roggero E, Rentsch C, Nitzsche E, Kueng M, Jochum W, Gillessen Sommer S, Eberli D, Beyer J, Spahn M, Cathomas R. [Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]. Praxis (Bern 1994) 2018; 107:1043-1051.
01.09.2018[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]
01.09.2018Praxis (Bern 1994) 2018; 107:1043-1051
Omlin Aurelius, Zwahlen Daniel, Wyler Stephen, Wild Damian, Templeton Arnoud J, Stenner Frank, Schmid Hans-Peter, Roggero Enrico, Rentsch Cyrill A, Nitzsche Egbert, Kueng Marc, Jochum Wolfram, Gillessen Sommer Silke, Eberli Daniel, Beyer Jörg, Spahn Martin, Cathomas Richard